Drug Trial Radar · NCT01211860
Pharmacokinetic Study of Diazoxide Choline in Hypertriglyeridemic Subjects
Last checked: Nov 19, 2026Latest source record: Jan 10, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
9
Actual
Start
Oct 2010
Primary completion
Nov 2010
Study completion Nov 2010
Sponsor
- Lead sponsor
- Essentialis, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Cetero Research, San Antonio
- First posted
- Sep 30, 2010
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Single group
- Masking
- None
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Once a day oral administration with DCCR is the optimal dosing regimen
Conditions
- Hypertriglyceridmia
Interventions
Diazoxide Choline Controlled-Release TabletDrug
DCCR 290 mg once a day for 10 days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Steady-state Pharmacokinetic profile of DCCRTime frame: 10 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Cetero
Fargo, North Dakota
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.